GC Medical Science Corporation (KOSDAQ:142280)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,105.00
+5.00 (0.16%)
At close: Sep 11, 2026

GC Medical Science Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-2,1623,6663,5811,797-3,581-21,202
Depreciation & Amortization
3,9933,9303,7863,8544,1073,831
Loss (Gain) From Sale of Assets
-21.840.34210.989.99-3.55-3.77
Loss (Gain) From Sale of Investments
-263.56-263.56428.89396.55-650.69-49.98
Provision & Write-off of Bad Debts
57.03-89-280.78265.8608.877,210
Other Operating Activities
4,771-812.24-2,781559.11-263.17,252
Change in Accounts Receivable
5,397-3,4913,896-1,432502.23908.72
Change in Inventory
-712.5260.69-2,384626.7315,324-9,254
Change in Accounts Payable
-3,4632,760-1,8751,058-2,273-7,545
Change in Other Net Operating Assets
761.41,233-921.56-2,894-2,891658.53
Operating Cash Flow
8,3577,1963,6614,24110,880-18,195
Operating Cash Flow Growth
-96.56%-13.69%-61.02%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,023-4,720-3,216-5,632-3,426-3,598
Sale of Property, Plant & Equipment
506.88941.1824.798.81300.15124.39
Sale (Purchase) of Intangibles
-329.13-179.29-61.18-250-75.95-
Investment in Securities
---1,793-2,472740.98
Other Investing Activities
83.42-71.84-5.15256.95-0-
Investing Cash Flow
-761.94-4,030-3,257-3,823-5,675-3,279

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-32,50012,00013,80029,940129,900
Long-Term Debt Issued
--20,000-30,000-
Total Debt Issued
38,10032,50032,00013,80059,940129,900
Short-Term Debt Repaid
--32,500-12,000-16,216-57,212-110,187
Long-Term Debt Repaid
--3,471-25,459-1,019-962.68-889.9
Total Debt Repaid
-45,703-35,971-37,459-17,235-58,175-111,077
Net Debt Issued (Repaid)
-7,603-3,471-5,459-3,4351,76518,823
Other Financing Activities
-14.69--4.96--0-0
Financing Cash Flow
-7,618-3,471-5,464-3,4351,76518,823

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
12.11--4.989.59-62.790.71
Net Cash Flow
-11.09-305.85-5,066-3,0076,908-2,650

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
7,3342,476445.24-1,3917,454-21,793
Free Cash Flow Growth
-456.00%----
Free Cash Flow Margin
7.18%2.28%0.43%-1.48%6.59%-21.43%
Free Cash Flow Per Share
334.0192.8016.65-51.96353.61-1034.47
Levered Free Cash Flow
215.11-4,440-4,684-8,25326,702-16,568
Unlevered Free Cash Flow
1,882-2,727-2,919-6,18528,499-15,835

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
580.55659.62465.26338.74667.841,134
Cash Income Tax Paid
31.368.1121.62134.9465.83232.3
Change in Working Capital
1,983763.57-1,285-2,64110,662-15,232